The Effect of the Oligofructose Supplementation on Body Weight in Overweight and Obese Children

January 15, 2014 updated by: Hanna Szajewska, Medical University of Warsaw

The Effect of the Oligofructose Supplementation on Body Weight in Overweight and Obese Children: a Randomized, Double Blind, Placebo-controlled Trial

This study is designed to assess the effect of oligofructose administration for 12 weeks on Body Mass Index (BMI) of overweight and obese children.

Study Overview

Status

Completed

Conditions

Detailed Description

The prevalence of childhood overweight and obesity is reaching epidemic proportions. There have been no effective methods for preventing or treating obesity in childhood so far prompting interest in new interventions. One potential option for obesity prevention is the use of the prebiotic oligofructose. Data from research on rodents shows that a high-fat diet enriched with oligofructose causes a decrease in energy intake, less weight gain and a lower level of triglycerides . A similar effect has been observed in healthy adults. Available evidence suggests that the addition of oligofructose to the diets of overweight or obese adults may increase satiety and thus reduce energy intake. Currently, there are no data on the effect of oligofructose in overweight and obese children.

Study Type

Interventional

Enrollment (Anticipated)

96

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Warsaw, Poland
        • Samodzielny Publiczny Dzieciecy Szpital Kliniczny

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children aged 7 to 18 years
  • BMI > 85 percentile
  • Signed informed consent

Exclusion Criteria:

  • Overweight / obesity secondary to genetic syndromes and/or endocrine diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Maltodextrin
Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
Experimental: Oligofructose
Orafti P95, Beneo-Orafti, Belgium,
Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
Other Names:
  • Orafti P95, Beneo-Orafti, Belgium

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
BMI z-score difference
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
BMI z-score difference
Time Frame: after 24 weeks of the intervention
after 24 weeks of the intervention
Percentage of weight reduction
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention
Difference in total body fat measured by Dual-Energy X-ray Absorptiometry (DEXA)
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention
Percentage of children with BMI-for-age > 85percentile
Time Frame: after 12 and 24 weeks of the intervention
after 12 and 24 weeks of the intervention
Mean BMI z-score
Time Frame: after 12 and 24 weeks of the intervention
after 12 and 24 weeks of the intervention
Self-reported energy intake (3-day diet record)
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention
Percentage of the children with abnormal fasting glucose
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention
Percentage of the children with dyslipidemias
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention
Percentage of the children with hypertension
Time Frame: after 12 weeks of the intervention
after 12 weeks of the intervention
Adverse effects
Time Frame: during intervention
during intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

June 27, 2012

First Submitted That Met QC Criteria

August 23, 2012

First Posted (Estimate)

August 27, 2012

Study Record Updates

Last Update Posted (Estimate)

January 16, 2014

Last Update Submitted That Met QC Criteria

January 15, 2014

Last Verified

January 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RG 4/2011

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Maltodextrin

Subscribe